ArticleHepatology (Baltimore, Md.)2021
Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA.
Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 118 citations in OpenAlex.
- Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.JMIR research protocols · 2026Article
- Role of social determinants and outcomes of patients with alcohol-associated liver disease referred for early liver transplantation: A multicenter analysis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Outcomes of Liver Transplantation Without Alcohol Abstinence in Alcohol-Associated Hepatitis With Original MELD Score ≥30.Annals of transplantation · 2026Observational
- The role of rehabilitation across the continuum of liver disease from cirrhosis to transplantation and beyond: A narrative review.PM & R : the journal of injury, function, and rehabilitation · 2025Review
- An AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease.Digestive diseases and sciences · 2025Article
- Regional variations and trends in liver transplantation practices across Europe.JHEP reports : innovation in hepatology · 2025Article
- Rural-Urban Disparities in Mortality Related to Alcohol-Associated Liver Disease by Race/Ethnicity in the United States From 1999 to 2022.Digestive diseases and sciences · 2025Article
- Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis.EClinicalMedicine · 2025Article
- Alcohol-Associated Liver Disease Mortality.JAMA network open · 2025Article
- The impact of liver transplantation on endpoint selection in alcohol-associated hepatitis trials.Hepatology communications · 2025Article
- Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.Clinical and molecular hepatology · 2025Article
- Acute alcohol-associated hepatitis: Latest findings in non-invasive biomarkers and treatment.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Disparities in Alcohol-Associated Liver Disease Hospital Encounters Amongst a Texas-Based Cohort of Patients.Alimentary pharmacology & therapeutics · 2025Article
- Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.Hepatology (Baltimore, Md.) · 2025Article
- Shifting mortality patterns of primary liver cancer in the United States: a 20-year analysis of disparities.Frontiers in public health · 2025Article
- Higher-Than-Expected Burden of Alcohol-Related Liver Diseases During COVID-19 Pandemic in the USA, with a Tapering Trend.Journal of general internal medicine · 2024Article
- The impact of surging transplantation of alcohol-associated liver disease on transplantation for HCC and other indications.Hepatology communications · 2024Article
- Hepatology consultation is associated with decreased early return to alcohol use after discharge from an inpatient alcohol use disorder treatment program.Hepatology communications · 2024Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Between-hospital care referrals for severe alcohol-related liver disease during the COVID-19 pandemic, 2020 to 2022.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe surge in unhealthy alcohol use during the COVID-19 pandemic may have detrimental effects on the rising burden of alcohol-associated liver disease (ALD) on liver transplantation (LT) in the USA. We evaluated the effect of the pandemic on temporal trends for LT including ALD. APPROACH AND
resultsUsing data from United Network for Organ Sharing, we analyzed wait-list outcomes in the USA through March 1, 2021. In a short-period analysis, patients listed or transplanted between June 1, 2019, and February 29, 2020, were defined as the "pre-COVID" era, and after April 1, 2020, were defined as the "COVID" era. Interrupted time-series analyses using monthly count data from 2016-2020 were constructed to evaluate the rate change for listing and LT before and during the COVID-19 pandemic. Rates for listings (P = 0.19) and LT (P = 0.14) were unchanged during the pandemic despite a significant reduction in the monthly listing rates for HCV (-21.69%, P < 0.001) and NASH (-13.18%; P < 0.001). There was a significant increase in ALD listing (+7.26%; P < 0.001) and LT (10.67%; P < 0.001) during the pandemic. In the COVID era, ALD (40.1%) accounted for more listings than those due to HCV (12.4%) and NASH (23.4%) combined. The greatest increase in ALD occurred in young adults (+33%) and patients with severe alcohol-associated hepatitis (+50%). Patients with ALD presented with a higher acuity of illness, with 30.8% of listings and 44.8% of LT having a Model for End-Stage Liver Disease-Sodium score ≥30.
conclusionsSince the start of COVID-19 pandemic, ALD has become the most common indication for listing and the fastest increasing cause for LT. Collective efforts are urgently needed to stem the rising tide of ALD on health care resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.